VALNEVA (EPA:VLA) | Finanzwire

Basculer en Français

9475	Companies
185441	Keywords
117779	Articles
99295	Press releases

Home
Companies
VALNEVA

BRIEF

published on 05/21/2025 at 13:36, 6 months 14 days ago

Valneva SE: Research Update Reaffirms Buy Rating, Raises Target Price

Target Price Financial Growth Valneva Market Forecast Lyme Vaccine
PRESS RELEASE

published on 05/21/2025 at 13:31, 6 months 14 days ago

Original-Research: Valneva SE (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research increases price target for Valneva SE to €8.10 following strong Q1/25 results and positive outlook on Lyme disease vaccine candidate, VLA15

First Berlin Equity Research Price Target Valneva SE Lyme Disease Vaccine Q1/25 Results
BRIEF

published on 04/26/2025 at 19:15, 7 months 8 days ago

Partial suspension of the use of Valneva's IXCHIQ® vaccine

Security Valneva France Vaccine Chikungunya
PRESS RELEASE

published on 04/26/2025 at 19:10, 7 months 8 days ago

Valneva Provides Update on Recommendation for Use of Its Chikungunya Vaccine by French Authorities
Valneva SE provides an update on the recommendation for the use of its Chikungunya vaccine by French authorities, focusing on adverse events in elderly people. The company is collaborating with regulators on next steps

Valneva SE Chikungunya Vaccine French Authorities Adverse Events Elderly
BRIEF

published on 04/18/2025 at 10:05, 7 months 17 days ago

Valneva Updates on Chikungunya Vaccine Recommendation in the U.S.

Valneva Chikungunya Vaccine IXCHIQ® ACIP Recommendation U.S. Travelers
PRESS RELEASE

published on 04/18/2025 at 10:00, 7 months 17 days ago

Valneva Provides Update on ACIP Recommendation for its Chikungunya Vaccine IXCHIQ® Among U.S. Travelers
Valneva provides update on ACIP recommendation for its chikungunya vaccine IXCHIQ® among U.S. travelers, highlighting new precaution for persons aged 65 years and ongoing safety monitoring

Valneva CDC Chikungunya Vaccine IXCHIQ® ACIP Recommendation
BRIEF

published on 04/09/2025 at 07:05, 7 months 26 days ago

First child vaccinated in Phase 2 study of S4V2 shigellosis vaccine

Valneva Phase 2 Shigellosis S4V2 Vaccine Pediatric Trial
PRESS RELEASE

published on 04/09/2025 at 07:00, 7 months 26 days ago

Valneva and LimmaTech Announce First Vaccination in Phase 2 Infant Study of Tetravalent Shigella Vaccine Candidate S4V2
Valneva and LimmaTech announce first vaccination in Phase 2 infant study of tetravalent Shigella vaccine candidate S4V2. Study aims to combat shigellosis, a deadly diarrheal disease

Valneva Phase 2 Study Shigella Vaccine Shigellosis LimmaTech
PRESS RELEASE

published on 03/20/2025 at 07:00, 8 months 16 days ago

Valneva Reports Full Year 2024 Results and Provides Business Updates and Outlook
Valneva SE reports solid full year 2024 results exceeding growth targets. Financial outlook for 2025 includes strong revenue growth and strategic investments. Key milestones and financial information discussed

Financial Results Valneva 2025 Outlook Vaccine Company Clinical Progress
BRIEF

published on 02/05/2025 at 07:05, 10 months ago

Valneva Achieves UK Approval for World's First Chikungunya Vaccine

Public Health Valneva Chikungunya Vaccine UK Approval Travel Safety

Accesswire

Published on 12/05/2025 at 02:35, 8 hours 46 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 8 hours 51 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 10 hours 21 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 12 hours 16 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 12 hours 21 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 11:14, 6 minutes ago

Halfords Group PLC: Director/PDMR Shareholding
Published on 12/05/2025 at 10:30, 51 minutes ago

Tradegate Exchange and Börse Berlin merge to form Tradegate BSX
Published on 12/05/2025 at 10:15, 1 hour 6 minutes ago

Wuxi’s Liangxi District: Where 3,000 Years of Jiangnan Culture Thrives
Published on 12/05/2025 at 09:40, 1 hour 41 minutes ago

Chery Partners with 2025 Asian Youth Para Games, Taking Center Stage in Global Sports with Passion and Aspiration
Published on 12/05/2025 at 09:30, 1 hour 51 minutes ago

REPLOID Group AG: Exhibitor at the BIOGAS Convention & Trade Fair in Nuremberg, Germany

Les Echos

Published on 12/05/2025 at 08:45, 2 hours 36 minutes ago

Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/04/2025 at 18:00, 17 hours 21 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 17 hours 36 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 17 hours 37 minutes ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 1 day 4 hours ago

bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health

View all LES ECHOS COMFI WIRE